Kiovig

Human Normal Immunoglobulin, the active ingredient in Kiovig, is an immunoglobulin presented as a solution for injection for intravenous use. It treats primary and secondary immunodeficiency diseases, immune‑mediated thrombocytopenia, Kawasaki disease, chronic inflammatory demyelinating polyneuropathy and Guillain‑Barré syndrome.

GNH USA supplies Kiovig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kiovig is an intravenous immunoglobulin used to replace deficient IgG and modulate immune activity in several immune‑related conditions. - Primary immunodeficiency diseases: provides IgG replacement to reduce infection frequency. - Secondary immunodeficiency (e.g., post‑bone marrow transplant): restores antibody levels to support immune recovery. - Idiopathic thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces inflammation and coronary artery complications. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability. - Guillain‑Barré syndrome: accelerates recovery of nerve function.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever or chills: typical infusion‑related reaction. - Fatigue: general feeling of tiredness after administration. - Nausea: occasional gastrointestinal upset. - Infusion‑related reactions: flushing, erythema, or mild hypotension. - Myalgia: muscle aches during or after infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate treatment. - Thromboembolic events: clot formation in veins or arteries. - Acute renal dysfunction: sudden decrease in kidney function. - Aseptic meningitis: inflammation of the meninges without infection. - Severe hemolysis: destruction of red blood cells. - Severe hypotension: marked drop in blood pressure during infusion.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Renal function: monitor patients with pre‑existing renal impairment. - Thrombotic risk: assess history of clotting disorders before infusion. - Infusion rate: follow recommended rates to minimize reactions. - Allergy: avoid in patients with IgA deficiency and anti‑IgA antibodies. - Pregnancy: use only if potential benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kiovig may interact with other therapies that affect immune function or coagulation. Major Interactions (Avoid): - Live vaccines: concurrent use can reduce vaccine efficacy and increase infection risk. - Immunosuppressants: may heighten susceptibility to infections. Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for altered clotting parameters. - Corticosteroids: may increase risk of fluid overload. - Diuretics: watch for changes in blood pressure during infusion.